# SHR-1701 in Combination With Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer

Source: https://onco.cc/trials/nct05300269/  
OnCo record `nct05300269` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Capecitabine, Oxaliplatin and Retlirafusp alfa in colorectal cancer, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting.

## Summary

SHR-1701 in Combination With Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer is a phase 2 interventional study registered as NCT05300269 by Suzhou Suncadia Biopharmaceuticals Co., Ltd., with 73 participants planned, started 2022-07-05 and due to reach its primary completion in 2024-07-31. Interventions recorded: SHR-1701；Capecitabine；Oxaliplatin.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05300269
- Phase: 2
- Setting: SHR-1701 in Combination With Radiotherapy and Chemotherapy as Perioperative Treatment for Resectable Locally Advanced Rectal Cancer, an Open Label, Single-arm, Multicenter Phase II Trial
- Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Enrolled: 73

## Sources

- ClinicalTrials.gov NCT05300269: https://clinicaltrials.gov/study/NCT05300269

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/), [Oxaliplatin](https://onco.cc/drugs/oxaliplatin/), [Retlirafusp alfa](https://onco.cc/drugs/retlirafusp-alfa/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)

---
JSON: https://onco.cc/api/v1/entities/nct05300269.json